Market Overview:

The companion diagnostics market is experiencing rapid growth, driven by expansion of precision medicine, advances in diagnostic technologies, and government and regulatory support. According to IMARC Group’s latest research publication, “Companion Diagnostics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2025-2033” the global companion diagnostics market size reached USD 7.6 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 22.3 Billion by 2033, exhibiting a growth rate (CAGR) of 12.11% during 2025-2033.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

Download a sample PDF of this report: https://www.imarcgroup.com/companion-diagnostics-market/requestsample

Our report includes:

• Market Dynamics
• Market Trends and Market Outlook
• Competitive Analysis
• Industry Segmentation
• Strategic Recommendations

Growth Factors in the Companion Diagnostics Market

• Expansion of Precision Medicine

Personalized medicine has become a game-changer in healthcare, and companion diagnostics sit right at its core by enabling targeted therapies tailored to an individual’s unique molecular profile. This approach is no longer just hype—data shows that over 60% of cancer drugs developed now rely on companion diagnostics to identify patients most likely to benefit, thereby improving response rates and minimizing harmful side effects for those unlikely to respond. Major healthcare systems are investing in large-scale precision medicine initiatives and clinical trials, and the alignment among pharmaceutical companies, diagnostics makers, and regulators has driven faster co-approvals and integration of these tests into routine care. In oncology alone, new companion diagnostics are rapidly being launched to support evolving therapies for breast, lung, and blood cancers, with organizations like Roche and Qiagen reporting expanded FDA approvals and partnerships, underscoring significant market momentum. Ultimately, the shift toward more precise, evidence-based treatment is steering global demand for companion diagnostics upward, especially as payers and clinicians seek better health and economic outcomes.​

• Advances in Diagnostic Technologies

The last few years have witnessed cutting-edge advances in companion diagnostics technology, which have greatly improved accuracy and speed without sacrificing cost-effectiveness. Next-generation sequencing (NGS) is at the heart of these innovations, now enabling multiplex genetic testing—checking multiple biomarkers in one go—for broader diagnostic reach at lower per-test costs. Digital pathology, machine learning, and flow cytometry-based solutions are also pushing the field forward, allowing clinicians to make smarter, faster choices using more data-rich insights. The market is seeing new launches of NGS and liquid biopsy companion diagnostics that can identify actionable mutations in patient samples in days rather than weeks, a shift that pays off in better real-world outcomes and reduced healthcare costs. Pharmaceutical companies are increasingly integrating these advanced diagnostics from development through clinical trials—Qiagen’s recent MRD partnership and BD’s collaboration with Quest Diagnostics exemplify the industry’s push for comprehensive, real-time solutions that benefit both providers and patients.​

• Government and Regulatory Support

Across continents, governments and regulatory bodies are stepping in to catalyze the adoption of companion diagnostics, recognizing their impact on public health, safety, and innovation. Agencies like the US FDA and Europe’s EMA have introduced dedicated pathways streamlining the review and approval process for companion diagnostics that pair directly with new drug therapies, effectively reducing the time and cost to bring critical treatments to patients. North America leads, but precision medicine pilot programs and biomarker-testing mandates are also taking root across Asia-Pacific and Latin America—with expanded healthcare funding that helps build diagnostic infrastructure and integrate these tests into routine care. Government-backed investment in hospital and laboratory expansion, combined with standardized codes for reimbursement, creates more consistent access and sparks broader adoption by both public and private healthcare providers. These factors, when combined, are removing major barriers and driving significant, sustained market growth for companion diagnostics worldwide.​

Key Trends in the Companion Diagnostics Market

• Surge in Liquid Biopsy Adoption

Liquid biopsy is fast changing the game in companion diagnostics, providing a non-invasive alternative to tissue biopsies for cancer and other diseases. The appeal is clear: these tests require only a blood sample, make frequent monitoring possible, and deliver faster results for both the patient and physician. Companies like Foresight Diagnostics are now rolling out highly sensitive MRD (minimal residual disease) assays, which can detect cancer recurrence with unprecedented detail and speed, down to a few cancer cells in a million healthy ones. The global rollout is particularly strong in urban oncology hubs and Asia-Pacific markets, where liquid biopsy adoption is scaling rapidly for multiple cancer types and is supported by broader clinical infrastructure and payer alignment. These innovations are expanding the toolbox for clinicians and are contributing to earlier intervention and improved long-term patient outcomes.​

• Rise of Multiplex and Multi-omics Platforms

One of the most exciting trends is the move toward multiplex and multi-omics companion diagnostics that can analyze several biomarkers or molecular signatures in parallel. Thanks to declining costs in next-generation sequencing technology, labs can now test for dozens of genetic alterations or protein markers at once, which is reshaping the clinical landscape. These solutions don’t just increase test accuracy; they actually open up more therapy options for patients by revealing a wider variety of actionable targets, especially in oncology and rare diseases. Strategic partnerships—like those between BD, Quest Diagnostics, and leading pharma firms—are accelerating the co-development of multiplex diagnostics and therapies, fast-tracking therapy access and driving innovation in personalized care. For healthcare providers, multiplexing means greater efficiency, better use of patient samples, and the ability to stay ahead as new biomarkers and therapies rapidly emerge.​

• Integration with Artificial Intelligence

Artificial intelligence (AI) has moved from buzzword to reality in the companion diagnostics world, powering smarter interpretation of complex datasets and improving clinical decision support. Advanced AI algorithms are now being used by high-throughput reference labs to flag rare genetic variants, provide real-time diagnostic recommendations, and even suggest new biomarker targets for therapies in development. The integration of AI into companion diagnostics workflows reduces human error and streamlines repetitive tasks, giving clinicians more time to focus on patient care while offering confidence in the diagnostic result. Several diagnostics giants and tech-forward labs have launched platforms that leverage machine learning for variant interpretation and reporting, ensuring not just faster turnaround, but also standardized data quality across different healthcare centers and countries. As a result, AI-driven innovations are set to reshape both the depth and the accessibility of personalized medicine worldwide.​

Leading Companies Operating in the Companion Diagnostics Industry:

• Abbott Laboratories
• Agilent Technologies
• BioMerieux
• Danaher Corporation
• Roche Holding AG
• Myriad Genetics Inc.
• Siemens Healthcare
• Thermo Fisher Scientific Inc.

Companion Diagnostics Market Report Segmentation:

By Product & Service:

• Assays, Kits and Reagents
• Software and Services

Assays, kits, and reagents dominate the market due to their critical role in biomarker detection and enabling targeted therapies.

By Technology:

• Immunohistochemistry (IHC)
• Polymerase Chain Reaction (PCR)
• In-situ Hybridization (ISH)
• Real-time PCR (RT-PCR)
• Gene Sequencing
• Others

Polymerase chain reaction (PCR) leads the segment owing to its widespread use in mutation detection and easy availability of diagnostic kits.

By Indication:

• Cancer
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Gastric Cancer
• Melanoma
• Others
• Neurological Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Others

Cancer holds the largest share, driven by high disease prevalence and increasing approvals of companion diagnostics for oncology treatments.

By End User:

• Pharmaceutical & Biopharmaceutical Companies
• Reference Laboratories
• Contract Research Organizations
• Others

Pharmaceutical & biopharmaceutical companies account for the highest demand as they integrate companion diagnostics into drug development.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America leads the market, supported by advanced healthcare infrastructure, strong regulatory support, and high adoption of precision medicine.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us:

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

United States: +1-201971-6302